HALMA ORD 10P – Consensus Indicates Potential -52.4% Downside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

HALMA ORD 10P with EPIC code (LON:HLMA) have now 12 analysts in total covering the company. The target price ranges between £16.20 and £9.45 with the average target price sitting at £13.70. Now with the previous closing price of £28.81 this now indicates there is a potential downside of -52.4%. There is a 50 day moving average of £27.68 and the 200 moving average now moves to £25.56. The market capitalisation for the company is £11b. Visit the company website at: http://www.halma.com

Halma provides technology solutions in the safety, health, and environmental markets. It operates through four segments: Process Safety, Infrastructure Safety, Environmental & Analysis, and Medical. The Process Safety segment offers specialized interlocks that control critical processes safely; instruments that detect hazardous gases; and explosion protection and corrosion monitoring systems. This segment serves the gas detection, industrial access control, pressure management, and safe storage and transfer markets. The Infrastructure Safety segment provides fire detection systems, specialist fire suppression systems, elevator safety systems, people and vehicle flow technologies, and security sensors. It serves the fire detection and suppression, People and Vehicle Flow, Security Sensors, and elevator markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; water, air and gases monitoring technologies; and systems for water analysis and treatment. It serves the optical analysis, water analysis and treatment, and environmental monitoring markets. The Medical segment provides critical fluidic components used by medical diagnostics and Original Equipment Manufacturers; laboratory devices and systems that provide information to understand patient health and enable providers to make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable positive outcomes across clinical specialties. This segment serves the life sciences, health assessment, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Halma plc (LON:HLMA) has released its full year results for the year ending 31 March 2024. Explore the financial details and dividend information here.
    Halma plc (LON: HLMA) releases its trading update for the financial year, showing strong growth and strategic investments. Full year results expected on 13 June 2024.
    Halma plc has appointed Giles Kerr as an independent non-executive Director, bringing valuable insights from his extensive experience in life sciences and technology sectors. Roy Twite will step down as a Director on 7 June 2024.

      Search

      Search